Would you consider trastuzumab deruxtecan for a patient with metastatic HER2+ colorectal cancer even if the cancer is RAS mutated?

The best available evidence for the role of trastuzumab deruxtecan (T-DXd) in HER2 positive (IHC 3+ or IHC2+/FISH+) colorectal cancer is the DESTINY-CRC01 study (cohort A) which showed a response rate of 45.3%, median progression-free survival of 4.1 months in patients who had >=2 lines of treatment...